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Two Novel Molecular Defects in the LCAT Gene 
Are Associated With Fish Eye Disease
Jan Albert Kuivenhoven, Anton F.H. Stalenhoef, John S. Hill, Pierre N.M. Demacker, A. Errami, 
John J.P. Kastelein, P. Haydn Pritchard
Abstract A 53-year-old man with a severely reduced H D L 
cholesterol level, dense corneal opacities, normal renal func­
tion, and premature coronary artery disease was investigated 
together with 16 members of his family. The proband was 
diagnosed with fish eye disease. As in previously reported 
patients with fish eye disease, the endogenous plasma choles­
terol esterification rate was near normal, yet lecithinxholester-
ol acyltransferase (LCAT) activity was almost absent when 
measured with exogenous HDL analogues used as substrate. 
Direct sequencing of the LCAT  gene revealed two novel 
missense mutations in exon 1 and exon 4, resulting in the 
substitution of Pro111 with Gin (P10Q) and Arg135 with Gin 
(R135Q), respectively. Both missense mutations were located 
on different alleles. Genetic analysis by polymerase chain 
reaction revealed 4 carriers of the P10Q and 3 carriers of the
R135Q defect. Functional assessment of both missense muta­
tions revealed that when exogenous HDL analogues were used 
as substrate, the specific activity of rLCATPm was 18% of wild 
type (WT); however, when LDL was used as substrate, the 
activity was 146% of WT. By contrast, rLC/17^Li5Q was inactive 
against both substrates. Thus, we conclude that the LC/4TR1JM) 
mutation is causative for complete LCAT deficiency and that 
the clinical phenotype of fish eye disease seen in this patient is 
due to the Pro10 mutation. The presence of premature coronary 
artery disease in the absence of other risk factors in this new 
case of fish eye disease raises questions regarding the risk of 
atherosclerosis, which has previously been reported to be 
nonexistent. [Arterioscler Thromb Vase Biol. 1996;16:294-303.)
Key Words 
acyltransferase
HDL deficiency 
fish eye disease
lecithin:cholesterol 
corneal opacities
umerous epidemiological studies have shown an 
inverse correlation of HDL cholesterol levels 
with the incidence and severity of CAD. To 
explain the role of HDL in lipid metabolism and athero- 
genesis, the model of “reverse cholesterol transport” is 
now widely accepted. In this model, the HDL particle is 
thought to mediate cholesterol transport from the pe­
riphery to the liver. The exact mechanism by which the 
HDL particle exerts this protective role in atherogenesis 
remains to be elucidated. Interestingly, a few rare he­
reditary disorders of HDL metabolism have been re­
ported with no apparent risk for CAD despite severe
HDL deficiency. FED, first described by Carlson and 
Philipson,1 is an example of such a disorder. Although 
I-IDL cholesterol is often reduced to below the detection 
level in these patients, corneal opacities are reported to 
be the only clinical hallmark. It is known that both FED 
and familial complete LCAT deficiency are caused by
in the L C A T  gene.2-13 However, the clinical 
presentation of the latter disorder includes hemolysis 
and renal failure in addition to the HDL deficiency. 
Because of the limited number of families studied, the
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risk for premature atherosclerosis is not well docu­
mented in either disorder.
In the present study, we describe compound heterozy­
gosity for two novel mutations in the LCAT gene in a 
53-year-old man with FED who suffers from severe 
premature CAD.
Methods
Proband
The 53-year-old proband was originally investigated at age 38 
for unstable angina pectoris. He was subsequently referred to 
our clinic because of an extremely low HDL cholesterol level. 
Angiography at the initial presentation revealed 95% stenosis 
of the right coronary artery and moderate, grade II aortic 
regurgitation, for which bypass surgery was performed together 
with replacement of the aortic valve. He developed recurrent 
chest pain 5 years later. On recatheterization, the aortic valve 
ippeared severely insufficient and had to be replaced. The 
bypass graft was patent, but the left anterior descending artery
stenosis. Since that time, he Ivad no further 
cardiac complaints. There were no other risk factors for 
cardiovascular disease, with the exception of cigarette smoking 
from age 18 until age 30. The family history was negative for 
premature cardiovascular disease.
On physical examination, the patient appeared well. There 
was severe corneal clouding, which had begun around puberty 
and had become more marked over the years. Loss of visual 
acuity was not apparent. Laboratory investigation revealed no 
glomerular disease or anemia.
r
C
Blood Samples and DNA Isolation
Blood from the proband and his family members was col­
lected in EDTA tubes after an overnight fast and placed 
immediately on wet ice. Plasma was separated from cells by 
centrifugation (1200# for 15 minutes at 4°C), frozen in liquid 
nitrogen, and stored at -70°C before shipment to Vancouver, 
where apos and various LCAT parameters were determined.
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Selected A bbrev ia tions an d  A cronym s
tipo
HK 
CAD
CE
apolipoprotein 
baby hamster kidney 
coronary artery disease 
esterified cholesterol
CER = cholesterol esterification rate 
CER-HDL = cholesterol esterification rate of HDL
CER-plasma
FC
cholesterol esterification rate of plasma 
free (unesterified) cholesterol
FED = fish eye disease 
LCAT = lecithin:cholesterol acyltransferase
LpA
PCR
P10Q
= lipoprotein Lp(a)
= polymerase chain reaction 
= clone containing a mutation at codon 10 
(substitution of Pro11 with Gin)
R135Q = clone containing a mutation at codon 135
(substitution of Arg1-’5 with Gin)
WT = wild type
Genomic DNA was extracted from white cells as described 
previously.14’15
Lipoprotein and Apolipoprotein Analysis
Cholesterol and triglyceride concentrations in plasma were 
measured by enzymatic reagents (Boehringer-Mannheim; 
Miles Laboratories) on a Multistat III centrifugal analyzer. 
Plasma HDL cholesterol was determined by the polyethylene 
glycol 6000 method.10 Total cholesterol and FC levels in the 
various lipoprotein fractions were determined by commercially 
available enzymatic methods (Boehringer-Mannheim). Plasma 
apo A-I and apo B-100 were measured by nephelometry. LDL 
protein was determined by the method of Lowry et al.17 
VLDL+IDL, LDL, H D L 2, and HDL., were separated by 
density gradient ultracentrifugation.18 Quantification of LpA-I 
particles in plasma was performed by electroimmunodiffusion 
in agarose gel with Hydragel LpA-I particle kits (Sebia). Lp A-I 
represents the amount of plasma apo A-I that is not present in 
the LpA-I:A-II particles, whereas LpA-I:A-II is calculated by 
subtraction of the LpA-I from the total amount of plasma apo 
A-I and LpA-I/A-II represents the amount of plasma apo A-I 
that is not present in the LpA-I particles.111
LCAT Activity, LCAT Concentration, and 
Measurement of the CER
LCAT activity was determined as described previously.20 
LCAT activity represents the ability of plasma to esterily 
cholesterol in an exogenously presented proteoliposome sub­
strate whereas CER reflects the esterification of cholesterol 
within the endogenous lipoproteins of the plasma. LCAT mass 
was measured by radioimmunoassay by Dr J J .  Albers (Univer­
sity of Washington School of Medicine, Seattle).21 C ER  was 
determined by measuring the rate of esterification of pHJcho- 
lesterol22 and was measured in both plasma and LDL/VLDL- 
depleted plasma. LDL/VLDL-depleted plasma was prepared 
by precipitation of Apo B-containing lipoproteins with phos- 
photungstate-MgCl2.23’24 CER-plasma and CER-HDL were 
calculated from FERs and plasma and HDL-FC levels, respec­
tively, as previously described.25
Amplification of LCAT Fragments by PCR
The 3 '-primers used in PCR reactions were biotinylated at 
the 5'-end with biotin phosphoramidite (Glen Research Corp). 
Three DNA fragments, encompassing exon 1/2, exon 3/4/5, and 
exon 6 of the LCAT  gene, were amplified by PCR from 
genomic DNA of the proband and a control subject by use of 
a DNA thermal cycler (Perkin Elmer Cetus). The amplification 
reactions were carried out in 10 mmol/L Tris-HCl (pH 9.0), 50 
mmol/L KC1, 0.1% wt/vol gelatin, 1.5 mmol/L MgCl2, 1% 
Triton X-100, 0.2 mg/mL bovine serum albumin containing 0.5
to 1.0 /xg genomic DNA, with final concentrations of 200 
jamol/L dNTPs and 0.2 to 0.3 /xmoI/L primers in a total volume 
of 50 /xL. After initial denaturation (10 minutes, 95°C), 0.3 to 
1.0 U thermostable DNA polymerase (Supertaq; HT Biotech­
nology Ltd) was added, followed by 30 cycles of 95°C (1 
minute), 65°C (1 minute), and 72°C (1 minute) with a final 
extension step of 10 minutes at 72°C.
Sequence Analysis
PCR products were precipitated with NH,|C1 and gel purified 
with Geneclean (Bio 101 Inc). Three to four micrograms of 
purified PCR product was incubated for 30 minutes at 37°C 
with 30 ¡xL streptavidin-coated beads (Dynal AS) in a total 
volume of 100 fiL  saline Tris-EDTA (1 mol/L NaCI, 5 mmol/L 
Tris, pH 7.4; 0.5 mmol/L Tris-EDTA). The supernatant was 
discarded and a magnet particle concentrator (MPC-E; Dynal 
AS) was used to separate phases. After three washing steps 
with 100 fxL saline Tris-EDTA, the beads were resuspended in 
10 fiL  0.1 mol/L NaOH and incubated for 10 minutes at room 
temperature to denature the DNA. Single-stranded DNA in 
the supernatant was recovered by neutralization, precipitated, 
and dissolved in deionized water for subsequent sequencing. 
The beads were rinsed with 60 n L 0.1 mol/L NaOI-I followed by 
three washing steps with 10 mmol/L Tris (pH 7.4) and 1 
mmol/L EDTA and resuspended in dH 20 .  Single-stranded 
DNA [35S]dATP sequencing was performed by the dideoxy 
chain termination method by use of nested primers and Seque- 
nase version 2.0 (United States Biochemical Corp) on both 
single-stranded templates.
Restriction Analysis of PCR-Amplified 
Genomic DNA
A 63-bp mutagenic primer with a 5' GC-clamp (5'- CCGC- 
C G C G C C C C G C G C C C G T C C C G C C G C -C C C C G C C C C C - 
TGGCTCCTCAATGTGCTCTTCCCGC-3') was used to am­
plify a 180-bp DNA fragment of the proband and his kindred. 
This primer creates a Bbv I cutting site when the C-to-Aw  
nucleotide substitution in exon 1 is present, 
digested with Bbv I, subjected to electrophoresis on a 3% 
agarose gel, and stained with ethidium bromide.
A 180-bp portion of the LC AT  gene of the proband and 
family members, spanning the site of the missense mutation in 
exon 4, was amplified by PCR. The G“ '*-to-A sequence change 
in exon 4 eliminates an A d  I cutting site in exon 4. PCR 
products were digested with A d  I subjected to electrophoresis 
on a 3% agarose gel and stained with ethidium bromide. The 
enzymes were used according to the instructions of the manu­
facturer (New England Biolabs).
Subcloning of PCR Products
PCR products encompassing exon I to 5 of the LCAT  gene 
of the proband were ligated into a pGEM -T vector (pGKM-T 
Vector System). Plasmid clones containing I he DNA fragment 
were analyzed for the presence of nucleotide changes in exon I 
(C'OT to A) and exon 4 (G ” IH to A); double-stranded DNA 
plasmid sequencing was performed by the dideoxy chain ter­
mination method as described above.
Mutagenesis of the LCAT cDNA
Both missense mutations were introduced into full-length 
LCAT  cDNA by use of unique restriction sites within the LCAT  
cDNA.
Exon 1 (C to Am)
A 364-bp DNA fragment containing the mutant 
in exon 1 was amplified by PCR with the genomic DNA of the 
proband. Gel-purified PCR product was digested with Nco I 
and Bpu\l()2l according to the manufacturer’s instructions
1  i * i \1
*  «
(New England Biolabs). A 100-bp DNA fragment containing 
the mutation was isolated from a 4% agarose gel /twhrinowr-
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Mannheim) with Mermaid (Bio 101 Inc). A four-end ligation 
was performed to insert this fragment as a cassette in the WT 
LCAT  cDNA in pNUT. Double-stranded plasmid DNA se­
quencing was used to identify a clone that contained the 
desired mutation at codon 10 but no other mutations (P10Q).
Exon 4 (G to A22'8)
Kpn I and ¿fasI-III (New England Biolabs) were used to digest 
a 428-bp PCR-ampIified DNA fragment of the proband con­
taining the mutant gene region in exon 4. A  57-bp DNA 
fragment encompassing the region of the mutation was isolated 
from a 2% agarose gel (50% low-melting point agarose; 
Boehringer-Mannheim) with Mermaid (Bio 101, Inc). After 
cloning, double-stranded plasmid DNA sequencing was per­
formed for identification of a clone containing the mutation at 
codon 135 (R135Q).
Stable Transfection of BHK Cells
The p N U T -L C 4 r  constructs, ie, pNUT-LC/lT-P10Q and 
pNUT-LG4 r-R135Q, were used to establish stable cell lines of 
BHK cells as previously described.26 The pNUT vector contains 
a mutant form of the dihydrofolate reductase gene that permits 
selection of cells containing the plasmid DNA by their survival 
in high concentrations of methotrexate. BHK cells were main­
tained in DMEM (Gibco-BRL) supplemented with 10% heat- 
inactivated fetal bovine serum. Stable transfection of BHK cells 
was performed by calcium phosphate coprecipitation as previ­
ously described.26
Analysis of BHK Clones
Clones expressing rLCAT  were identified by LCAT enzyme 
activity and solid-phase LCAT immunoassay as previously 
described.27 One cell line of each clone was selected for further 
analysis. The specific enzyme activities of the WT and mutant 
vLCATs were determined with H D L analogues and LDL used 
as substrates. LDL was prepared by preparative ultracentrifu­
gation from blood collected from normal volunteers after 12 
hours of fasting. The LDL fraction was dialyzed extensively at 
4°C against 0.01 mol/L Tris-HCl (pH 7.4) containing 0.15 mol/L 
NaCl and 0.005 mol/L EDTA. After heat inactivation at 56°C 
for 30 minutes to eliminate endogenous LCAT activity, the 
concentration of unesterified cholesterol was determined en­
zymatically by a reagent kit (Boehringer-Mannheim).
Results
Genetic Analysis
The intron-exon boundaries and the coding regions of 
the LCAT gene were sequenced in the proband and a 
normal control subject. Direct sequencing revealed het­
erozygosity for two novel missense mutations (Fig 1A 
and IB): (1) a C-to-A sequence change in exon 1, 
resulting in the substitution of a proline (CCG) for a 
glutamine (CAG) at position 10 of the mature protein, 
and (2) a G-to-A base substitution in exon 4, introducing 
an arginine (CGG) for a glutamine (CAG) at position 
135. To determine whether these mutations were either 
in cis or trans conformation, an LCAT fragment encom­
passing both mutations (exon 1 to exon 5) was amplified 
and cloned. It was shown by sequence analysis that 
clones either contained the C-to-A point mutation in 
exon 1 or the G-to-A point mutation in exon 4 (results 
not shown), thereby demonstrating that the mutations 
were present on different alleles. The mutation in exon 1 
neither created nor eliminated a restriction site for a 
known endonuclease. To screen the genomic DNA of 
the family members for the presence of this mutation, a 
mutagenic PCR was devised that introduced a Bvb I 
cutting site when the mutation was present (Fig 2A).
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Fig 1. Autoradiograms of DNA sequencing gels of PCR-ampli- 
fied LCAT fragments of the proband’s genomic DNA showing 
heterozygosity for two novel missense mutations. A, A C-to-A 
nucleotide substitution in exon 1 results in a proline for glutamine 
substitution at position 10 in the mature protein. B, A G-to-A 
sequence change in exon 4 results in the substitution of an 
arginine for a glutamine residue at position 135.
Analysis of family members revealed four additional 
heterozygotes for this mutation. The G-to-A point mu­
tation in exon 4 eliminates an Aci I restriction site. A 
180-bp fragment of the LCAT gene, encompassing the
B
A
M 1
M 1
246
123
246
123
Fig 2. PCR-based DNA restriction analysis to detect the pres­
ence of the missense mutations in exon 1 and exon 4 of the 
LCAT gene (see Fig 1). Both panels represent an example of the 
screening methods for mutation detection.
A, The region encompassing the point mutation in exon 1 (Fig 
1A) was amplified by PCR in both a normal and heterozygous 
subject by use of a mutagenic primer, creating a Bbv I cutting 
site when the C937-to-A nucleotide substitution was present. A 
3% agarose gel stained with ethidium bromide is shown. Lane M 
shows a molecular size standard (length of the fragments in base 
pairs on the left). Lane 1: Undigested PCR-product of 180 bp. 
Lane 2: PCR product of a normal subject digested with Bbv I, 
showing the absence of a restriction site. Lane 3: The presence 
of a Bbv I cutting site in a heterozygote for the mutation; the 120- 
and 60-bp fragments indicate heterozygosity.
B, A 180-bp portion of the LCAT gene spanning the site of the 
missense mutation in exon 4 (Fig 1B) was amplified by PCR in 
both a normal and a heterozygous subject. The G2218-to-A 
sequence change eliminates an Aci I cutting site in exon 4. Lane 
M shows a molecular size standard. Lane 1: Uncleaved PCR 
product of 180 bp. Lane 2: PCR product of a normal subject 
digested with Aci I showing the presence of a cutting site on 
both alleles. Lane 3: Uncleaved PCR product as the result of the 
elimination of an Aci I site in a sibling heterozygous for the 
mutation.
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T able 1. Lipids and Lipoproteins
Status TC, mmol/L LDL-C, mmol/L HDL-C, mmol/L TG, mmol/L
Proband
11-1 5.66 4.80 0.17 2.38
Heterozygous for P10Q
1-1 5.56 4.30 0.95 1.27
II-3 6.01 4.69 0.79 1.38
III-2 4.34 3.56 0.64 0.85
III-4 3.61 2.42 1.16 0.41
Mean+SD* 4.88±0.95 3.74±0.86 0.89+0.19 0.98±0.38
Heterozygous for R135Q
II-7 4.85 3.53 0.94 1.31
111-1 4.55 3.48 0.83 1.31
III-7 3.48 2.34 1.01 0.67
M eaniSD 4.29±0.59 3.12±0.55 0.93+0.07 1,10±0.30
All heterozygotes
Mean±SD 4.63+0.87 3.47±0.81 0.90+0.16 | 1.03+0.36
Normal
II-2 6.47 5.01 1.24 1.02
II-4 5.11 3.14 1.27 1.26
II-5 6.25 4.56 1.31 1.06
II-6 5.77 4.32 1.01 1.71
II-8 5.26 2.85 2.05 1.51
III-3 4.06 2.39 1.24 1.27
III-5 4.65 2.77 1.67 0.97
HI-6 3.10 1.61 1.24 0.79
III-8 4.05 2.31 1.52 1.04
M eaniSD 5.29±0,99 3 .35±1 .06 1.41+0.29 1.13±0.29
TC indicates total cholesterol; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides. Status 
of family members is determined by DNA analysis.
*Mean±SD of all heterozygotes.
tP<.002, heterozygotes vs normal subjects (Student’s t test).
site of the mutation, was amplified by PCR. Digestion of 
normal LCAT sequence resulted in two DNA fragments 
of 45 and 135 bp, respectively, of which only the 135-bp 
fragment is clearly visible when subjected to electro­
phoresis with a 3% agarose gel (Fig 2B, lane 2). The 
undigested PCR product in lane 3 of Fig 2B is indicative 
for heterozygosity due to the loss of a cutting site on one 
allele. When the DNA of the family members was 
screened for the presence of this mutation, three more 
carriers of this mutation were identified (Fig 3). Restric­
tion analysis confirmed the proband’s compound het­
erozygosity for both point mutations in exon 1 and 4. 
The complete family tree of the studied kindred is shown 
in Fig 3, which illustrates the pattern of inheritance for 
each mutation.
1 6 8
Fig 3. Family tree of the investigated kindred. The proband 
-1) was shown to be a compound heterozygote for two 
missense mutations in exon 1 and exon 4, respectively, resulting 
in a Pro10-to-Gln and an Arg135-to-Gln substitution in the mature 
protein (Fig 1). Screening of family members for the presence of 
these mutations was achieved by restriction analysis of PCR 
products from genomic DNA spanning the regions of the muta­
tions (Fig 2). Squares and circles indicate males and females, 
respectively; left-sided shading (gray), heterozygosity for Pro10 to 
Gin; right-sided shading (black), heterozygosity for Arg135 to Gin; 
and diagonal bar, deceased.
Lipoprotein and Apo Analysis
Plasma lipoprotein concentrations of the proband and 
all family members are shown in Table 1. The carrier 
status of family members was determined by use of 
PCR-based DNA analysis, as described above. The 
plasma cholesterol level in the proband (II-l) was in the 
normal range, but he showed mildly elevated triglyceride 
levels and LDL cholesterol levels. HDL cholesterol level 
was reduced to <10% of the levels exhibited by other 
members of his family. Heterozygotes had significantly 
reduced HDL cholesterol levels (PC.Q02 by Student’s t 
test) compared with unaffected family members. Apo 
and HDL subfraction data are summarized in Table 2. 
The proband was characterized by severely reduced 
plasma apo A-I concentrations and elevated apo B-100 
levels. Plasma concentrations of apo A-I in heterozy­
gotes were significantly decreased to «=«70% of apo A-I 
levels exhibited by unaffected family members (Pc.003 
by Student’s t test). The HDL deficiency in the index 
patient was due to a specific near-total loss of LpA-I/ 
A-II particles, whereas LpA-I levels were half of normal. 
The decrease in HDL 
however, was reflected by a significant decrease of both
in
LpA-I and LpA-I/A-II particles (P c .005 and Pc.019
respectively, versus normal levels).
VLDL+IDL, LDL, H D L 2,
fractions were separated by density gradient ultracentrif­
ugation (Fig 4) and the FC and CE contents determined 
in all family members (Table 3). Fig 4 illustrates the 
HDL deficiency in the proband and an apparent selec­
tive loss of H D L2 in two heterozygotes for the P10Q and 
the R135D defect (subjects 1-1 and IÏI-1, respectively).
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T able 2. Apo B-100, Apo A-l, and HDL Subtractions
Apo B, Apo A-l, LpA-l, LpA-l:A-ll, LpA-l,
Status mg/dL LDL-C/Apo B mg/dL mg/dL mg/dL %
Proband
11-1 172 1.08 31 30 1 97
Heterozygous for P10Q
1-1 108 1.54 129 43 86 33
II-3 104 1.74 112 52 60 46
III-2 88 1.56 97 42 55 43
ill-4 51 1.83 127 54 73 43
M eaniSD* 8 8 i2 3 1.67i0.1 116+13 48±5 6 9 i1 2 41 i 5
Heterozygous for R135Q
II-7 90 1.51 132 40 92 30
111-1 93 1.44 119 47 72 39
III-7 56 1.61 109 37 72 34
M eaniSD 8 0 i1 7 1,52±0.1 120±9 41 ± 4 79+9 35+4
All heterozygotes
M eaniS D 84 i21 1.6+0.13 118+12t 45±6 7 3 i1 2
CDTÎCOCO
Normal
II-2 120 1.61 147 54 93 37
II-4 83 1.46 154 78 76 51
II-5 110 1.60 156 61 95 39
II-6 111 1.50 124 50 74 40
II-8 76 1.45 212 87 125 41
ill-3 57 1.62 145 68 77 47
III-5 70 1.53 201 72 129 36
III-6 73 0.85 140 47 93 34
III-8 55 1.62 161 55 106 34
M eaniS D 84 ±23 1.47+0.23 160 i27 64±13 96±19 40±5
LDL-C indicates LDL cholesterol; LpA-l, lipoproteins containing apo A-l only; LpA-l/A-ii, lipoproteins 
containing apo A-l and apo A-ll. Status of family members is determined by DNA analysis.
*Mean±SD of all heterozygotes.
tP < .003 , heterozygotes vs normal subjects (Student’s t test).
Lipid analysis of each class of lipoprotein indicated no 
significant differences when VLDL+IDL and LDL li­
poprotein fractions of heterozygotes were compared 
with those of normal subjects. By contrast, VLDL+IDL 
FC and LDL FC were increased in the proband com­
pared with control subjects. Both HDL2 FC and HDL3 
FC were reduced to *»35% of normal in the proband. 
H D L2 FC was significantly decreased in heterozygotes 
(Pc.07 by rank, sum two-sample test), whereas HDL3 FC 
was normal compared with unaffected family members. 
Furthermore, the FC/CE ratio in the PIDL2 fraction was 
significantly higher in heterozygotes compared with un­
affected siblings (P c .03 by rank sum two-sample test).
':
VLDL+IDL
LDL
HDL-2
HDL-3
I : r -‘
my
pars”
II-8 1-1 III-1 I1I-5
Fig 4. Density gradients after ultracentrifugation of plasma from 
the proband (P), two unaffected siblings (li-8 and ill-5), and two 
carriers of either the Pro10-to-Gln defect or the Arg135-to-Gln
defect (1-1 and 111-1, respectively).
LCAT Activity and Endogenous Estérification Rate
Data on LCAT activity and related parameters are 
summarized in Table 4. LCAT activity was measured in 
both whole plasma and VLDL- and LDL-depleted 
plasma with HDL analogues used as substrate. LCAT
T able 3. VLDL+IDL, LDL, HDL2, and 
HDL; Subtractions
FC,
mmol/L
CE,
mmol/L Ratio
VLDL+LDL
Proband 0.47 0.55 0.84
Heterozygotes (n=7) 0.21 i0 .0 8 0.24+0.20 1.29 + 0.92
Normal subjects (n=9) 0.23±0.08 0.35+0.21 0.90±0.30
LDL
Pro band 1.56 3.17 0.49
Heterozygotes (n=7) 0.95±0.21 2.24+0.51 0.41 ±0.02
Normal subjects (n=9) 0.83+0.27 2.09+0.72 0.40±0.04
HDL2
Proband 0.04 0.02 2.00
Heterozygotes (n—7) 0.08+0.03* 0 .1 3 i0 .0 7 f 0.63±0.18t
Normal subjects (n=9) 0.12i0 .05 0 .27 i0 .15 0.49+0.10
HDLa
Proband 0.07 0.03 2.50
Heterozygotes (n=7) 0.16±0.03 0.46i0 .08 0.35+0.09
Normal subjects (n=9) 0.18±0.04 0.62±0.10 0.29±0.05
FC and CE and their ratio in the lipoprotein fractions VLDL+IDL 
(d<1.019 g/mL), LDL (1.019<d<1.063 g/mL), HDL2 (1.163<d<1.10 
g/mL), and HDLa (1.10<d<1.125 g/mL).
Status of family members is determined by DNA analysis. Values 
represent m eaniSD of specified groups.
*P<.072; t /3<-050; tP c .026 , heterozygotes vs normal subjects (rank 
sum two-sample test). No differences were detected between heterozy­
gotes carrying either the Pro10-to-Gln or the Arg135-to-Gln defect.
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Fig 5. Activities of rLCAT proteins. Mutant LCAT enzymes 
containing either the Pro10-to-Gln or Arg135-to-Gln defect were 
expressed in BHK cells and assayed for specific activity with 
HDL analogues (A) and LDL-C (B) used as substrate. Specific 
activities are expressed as percentage of WT, whereas absolute 
activities were in nanomoles of cholesterol esters generated per 
hour per microgram of rLCAT. Values in A and B represent the 
m eaniSD of three independent assays carried out in duplicate. 
Error bars represent SD.
activity in the plasma of the proband was decreased to 
<8% ot the activity of unaffected family members, 
whereas CER-plasma was only slightly reduced. Choles­
terol esterification associated with HDL particles in the 
proband was only one third of that in control subjects. 
Heterozygotes showed *=«60% of normal LCAT activity 
in plasma and 70% of normal activity in plasma depleted 
of apo B-containing lipoproteins. The decrease of cho­
lesterol esterification in heterozygotes in both whole and 
VLDL/LDL-depleted plasma (PC.01 and P<.Q07, re­
spectively, by Student’s t test) was mainly caused by the 
low CER of subjects III-4 and III-7, who interestingly 
had low triglyceride levels and plasma FC but high 
HDL2. Except for subject 1-1, the proband and all 
heterozygous carriers presented with lower LCAT con­
centration and a tendency toward lower specific activity 
compared with unaffected family members.
In Vitro Expression of rLCAT
To assess the functional significance of the amino acid 
substitutions Pro10 with Gin (P10Q) and Arg135 with Gin 
(R135Q) in the LCAT protein, both mutant enzymes 
were expressed as recombinant proteins in BHK cells. 
The ability of these mutant proteins to esterify choles­
terol in HDL analogues and LDL is shown in Fig 5.
When HDL were as substrate, the
specific activity of LCATVWQ was 18±0.5% of WT; 
however, P10Q showed higher specific activity when 
LDL was used as substrate (146±19.6% of WT). 
LCATR|35q showed low activity against HDL analogues 
(1.2±0.5% of WT) as well as against LDL (3.6±0.7% 
of WT).
Discussion
Two Novel M utations Associated With FED
In the present study, we describe a 53-year-old man in 
whom severe HDL deficiency, dense corneal opacities, 
decreased LCAT activity, and near-normal CER were 
pathognomonic for FED. The presence of premature 
atherosclerosis in this subject at age 38 while additional 
risk factors were absent is of particular interest.
The proband was shown to be compound heterozy­
gous for two novel missense mutations in exon 1 and 
exon 4 of the LCAT gene, resulting in the substitution of 
Pro111 with Gin (P10Q) and Arg135 with Gin (R135Q), 
respectively. On screening of the family’s DNA for the 
presence of both mutations, four carriers of the P10Q 
defect and three carriers of the R135Q defect were 
identified. Their carrier status was in keeping with 
reduced LCAT activity, indicating the sensitivity and 
specificity of this assay.
To properly classify LCAT gene defects that may be 
causative for either FED or LCAT deficiency, the effects 
of each mutation on LCAT activity must be defined by in 
vitro analysis and compared with in vivo data. This is 
essential in cases of compound heterozygosity such as 
reported in the present study. In vitro expression of both 
mutations present in this family was performed to study 
the functional effects of these nucleotide changes on the 
LCAT protein. Mutated LCAT cDNAs were ligated into 
the pNUT expression vector and used for stable trans­
fection of BHK cells. rLCATvm  was secreted at normal 
levels compared with WT xLCAT and was shown to be 
only partially active when HDL analogues were used as
WT)
We
WT)
expression of the T hr12:l-Ile defect in COS-I cells.27 On 
the other hand, although sufficient rLCATlui5D protein 
was secreted, the mutant protein had negligible catalytic 
activity against both substrates, which was characteristic 
of classic LCAT deficiency. Therefore, we conclude that 
compound heterozygosity for P10Q and R135Q under­
lies HDL deficiency in the proband, whereas the P10Q 
defect dominates the biochemical phenotype and there­
fore is responsible for the clinical expression of FED. 
Furthermore, the in vivo generation of cholesteryl esters 
in the proband’s plasma is limited to the LDL/VLDL 
fraction and is maintained by the apparent enhanced 
activity of LCATvn)0 on LDL. In contrast, this 
LCATP1QQ in heterozygotes does not seem to 
substantially to cholesterol esterification, as shown by 
identical CER values in both P10Q and R135Q carriers.
This
activity is not rate-
LCAT concentration or
m
cholesteryl esters in plasma.
Different nucleotide changes in the same codons were 
described earlier by Skretting and Prydz2 and
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T able 4. LCAT Activities, LCAT Mass, and CERs
Plasma VLDL/LDL Depleted Plasma
Status
LCAT Activity, 
nmol • h_i • mL-1
LCAT
Concentration,
(/xg/mL)
Specific Activity, 
nmol • h“1 • jug"1
CER, 
nmol • h-1 ■ mL~1
LCAT, 
nmol • h-1 • mL
CER,
-i nmol • h“1 • mL-1
Proband
11-1 2.8 3.28 0.85 101 4.6 11.0
Heterozygous for P10Q
1-1 18.8 7.90 2.38 105 18.9 30.3
II-3 20.1 ND 103 19.1 33.8
ill-2 14.4 3.41 4.22 101 18.3 27.2
ill-4 22.0 ND • • « 62 14.4 25.6
Mean±SD 19±2.8 » « • 93±18 18±2 29±3
Heterozygous for R135Q
II-7 20.3 3.65 5.56 108 21.8 38.6
111-1 19.2 2.90 6.62 123 19.6 34.4
III-7 22.3 22.3 3.15 7.08 70 20.1
M eaniSD 20.6±1.3 3.23 ±0.31 6.42+0.64 100+22 20.5 ±1 33+6
All heterozygotes
Mean±SD 19.6±2.4 (4.2 ±1.9) (5.17+1.7) 96+20* 18.9+2.1 30.7±4.7t
Normal
II-2 29.7 4.67 6.36 129 25.0 39.4
li-4 33.5 ND * f * 109 26.8 43.6
II-5 34.7 5.70 6.09 124 26.8 39.1
II-6 35.1 4.69 7.48 132 39.4 50.4
II-8 35.9 5.55 6.47 114 23.5 39.9
ill-3 31.3 ND 1  • 9 134 25.0 46.2
ill-5 31.0 4.16 7.45 111 19.7 37.5
ill-6 36.2 4.74 7.64 135 32.0 48.0
ill-8 34.7 6.18 5.61 103 27.9 34.4
Mean±SD 33.6±2.2 5.1 ±0.7 6.73+0.7 121+11 27.3±5.3 42.1 ±5
LCAT activities (using exogenous proteoliposomes as substrate) and endogenous CERs were determined in both plasma and VLDL+LDL-depleted 
plasma. Status of family members is determined by DNA analysis.
*P<.01; ^ < .0 0 7 , heterozygotes vs normal subjects (Student's f test).
et al.13 A homozygous C-to-T substitution in codon 10 
altering Pro10 to Leu (P10L) was identified in the 
original Swedish FED patients, whereas a C-to-T muta­
tion in codon '135 resulting in the exchange of an Arg135 
for Trp (R135W) in combination with a frameshift in 
exon 1 was identified in a Canadian patient who suffered 
from classic LCAT deficiency. Although these amino 
acid substitutions at positions 10 and 135, respectively, 
differ from those in our proband, the effects on the 
LCAT protein are identical. Both R135Q and R135W 
defects (unpublished data, 1994) result in a catalytically 
inactive enzyme, whereas LCATm)Q and LCATPm, (un­
published data, 1994) are causative for an FED pheno­
type, since both retain the ability to esterify cholesterol 
in LDL.
Severe Premature Atherosclerosis in the 
Index Patient
The major clinical finding of the present study is the 
clear presence of premature atherosclerosis in the pro­
band despite the absence of other risk factors. In addi­
tion, we observed premature CAD in two male probands 
in another Dutch FED family.28 Although this observa­
tion must not be overinterpreted, it causes us to question 
the earlier assumption that the FED phenotype is not 
associated with increased risk of CAD.13 It is difficult to 
evaluate this issue, since relatively few patients with 
FED have been described and no rigorous statistical 
analysis is possible. It is vital, however, that some
consensus is reached with respect to risk for newly 
discovered probands and their family members.
We have reviewed the published clinical data on 
patients with proven FED (Table 5). The two original 
Swedish probands, both female (kindred I1), did not 
present with premature CAD. The index patient was 
referred to the clinic because of hypertriglyceridemia. 
Atherosclerosis in this kindred developed with age: the 
older sister had a myocardial infarction at age 77; the 
father, who suffered from the same eye disease, died at 
age 76 of a myocardial infarction. An unrelated Swedish 
female proband was alive and well at age 70 (kindred 
II29). Her referral basis was ophthalmology. A third case 
of FED was presented by Frohlich et al3(): a 16-year-old 
boy was noted to have low IiDL cholesterol and corneal 
opacities (kindred III). This patient was identified by 
molecular diagnosis as suffering from FED (unpublished 
data, 1994). Although there was some histoiy of cardio­
vascular disease in his mother’s family, many relatives 
lived into their 90s. His father, an apparent heterozy­
gote, underwent coronary bypass surgery at age 65. 
Funke and coworkers5 (kindred IV) were the first to 
report premature atherosclerosis in FED: the index 
patient had suffered since the age of 50 from angio- 
graphically assessed two-vessel CAD with a 60% stenosis 
of the anterior interventricular artery and a 50% stenosis 
of the posterior interventricular artery, whereas his 
brother was reported to have experienced angina pecto­
ris since the age of 60. The family history, however, was 
negative with regard to any increased risk for CAD. Two
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Table 5. Partial LCAT Deficiency and Risk of Atherosclerosis
Kindred
Country of 
Origin
Molecular
Defect(s)* Sex
Age at 
Investigation, y
Presence 
of CAD
Age of 
Onset, y Reference
1 Sweden Pro10 F 76 No 1 f  1 1
F 61 No
II Sweden Pro10 F 70 No *  4 • 29
III Canada Met262-Lys M 16 No < « * 30
Asn391-Ser
IV Germany Thr123-lle M 57 Yes 50 5
M 68 Yes 60
V The Netherlands Thr123-lle M 32 No 5, 31
M 37 Yes 51
VI Germany Thr123-lle M 66 No t  « t 3
Thr3<l7-Met
VII Algeria Del300 M 53 No *  « « 32
F 49 No M ♦ *
F 50 No a « i
VIII The Netherlands Asp131-Asn M 58 Yes 43 28
M 64 Yes 54
Pro10-Gln
IX The Netherlands Arg 135-Gln M 38 Yes 38 Present study
The probands are either homozygous when a single mutation is depicted or compound heterozygous for two mutations.
unrelated Dutch probands (kindred V5-31) were brought 
to our attention by an ophthalmologist. Although these 
patients were originally referred as healthy and without 
any signs or symptoms of atherosclerosis, the elder 
brother suffered from angina that required bypass sur­
gery at age 51 (unpublished data, 1994). Recently, Klein 
et al3 presented a 66-year-old German patient with FED 
(kindred VI). His excellent condition to date could be 
related to his remarkable lifestyle: physically very active, 
lifelong low-fat diet, nonsmoker. The seventh kindred 
with FED was reported by Clerc et al32: a 53-year-old 
man and two of his sisters, 49 and 50 years old, respec­
tively, had good general health and showed no signs of 
atherosclerosis. However, the proband of this family and 
his two sisters were homozygous for the Leu10'1 deletion.4 
This mutation is associated with a biochemical FED 
phenotype that differs from other FED patients in that 
the near-normal cholesterol esterification is not accom­
panied by specific loss of activity on HDL. This might 
have implications for the risk to develop atherosclerosis. 
As mentioned above, we have recently described a large 
Dutch kindred (kindred VIII28) in which the two male 
homozygous individuals had proven CAD at age 43 and 
54, respectively.
This analysis of literature and an evaluation of the 
current condition of FED patients further indicates the 
potential for the early onset of atherosclerosis. We 
believe that the apparent longevity of the original Swed­
ish patients (kindreds I and II) and the young age of the 
Canadian proband (kindred III) may have provided an 
early bias in the assessment of risk for CAD. It is now 
clear that several of the male patients with FED do 
indeed suffer from CAD, and this is exemplified by 
severe premature atherosclerosis in the proband re­
ported in the present study (Table 5).
It is important to recognize the potential for selection 
bias in all kindreds described here, since the reason for 
referral may have an impact on the relative number of 
patients who appear to develop premature CAD. For 
example, it is obvious that patients referred for diagnosis 
by cardiologists are far more likely to have CAD than 
those referred by ophthalmologists or general practitio­
ners who note the corneal opacity or HDL deficiency. 
Therefore, it seems likely that several families with FED 
remain undiagnosed or misdiagnosed. Thus, any accu­
rate prediction of FED-induced risk of CAD must be 
based on a representative sample of patients that in­
cludes those who are asymptomatic with respect to 
CAD. Since HDL deficiency is characteristic of all cases 
of FED, large-scale screening of lipid profiles will likely 
identify new families with FED who have not been 
investigated as a consequence of the presence of disease. 
Overall, no definitive conclusion regarding FED and risk 
of CAD can be made until more families with FED are 
identified.
If the cause of CAD in the family in the present study 
is related to FED, the mechanism involved cannot be 
determined from this study. It may not simply be related 
to changes in HDL concentration and structure but 
could be due to increased LDL cholesterol and apo B 
levels. In contrast, it is tempting to that
inactive or partially active LCAT increases the risk for 
atherosclerosis, supporting the protective action of an 
intact LCAT protein against CAD, by its role in reverse 
cholesterol transport. Although total plasma cholesterol 
esterification is near normal in FED, the lack of normal 
maturation of HDL particles (as described below) could
Structural Changes in the HDL Pool of 
Homozygotes and Heterozygotes
The changes in lipids and apoprotein levels in the 
plasma of the proband were not markedly different from 
those reported earlier for other patients with FED. Of 
particular interest, however, is our observation that the 
decreased HDL level is due to a near-absolute deficiency 
of LpA-I/A-II particles. This phenomenon has been 
observed in other patients with FED33 (eg, kindreds III, 
VI, and VII; Table 5), but to a less marked degree. The 
pathophysiological basis of the loss of apo A-II-contain­
ing particles appears to be a marked hypercatabolism of 
apo A-II. Since this effect is also seen in LCAT defi­
ciency, Rader et at33 concluded that LCAT activity is
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required to maintain the maturation and accumulation 
of apo A-II-containing HDL particles.
The effects of heterozygosity for either allele on the 
biochemical phenotype in this family are also interesting. 
The small number of patients carrying each mutation 
makes it difficult to compare the different heterozygotes; 
the total heterozygous group is different from those 
family members who are genetically unaffected. We 
observed a significant decrease in both HDL cholesterol 
and apo A-I levels in heterozygotes compared with 
unaffected individuals. In addition, we noted a 46% 
decrease in H D L2 cholesterol levels but only a 23% 
decrease in HDL3 cholesterol levels. This reduction in
*■ *
HDL cholesterol level was associated with a highly 
significant decrease of LpA-I levels (P<.005) and, to a 
lesser extent, LpA-I/A-II levels (PC.019) in heterozy­
gotes. Clearly, the heterozygous state for FED in this 
family affects both the total amount and subclass distri­
bution of the HDL pool. Since a significant decrease of 
both H D L2 and LpA-I levels would be associated with 
increased risk of CAD in the general population, we 
believe that the relative risk for CAD in individuals who 
are heterozygous for defects of the LCAT gene requires 
further evaluation.
Conclusions
In the current study, we report a patient with FED 
who was shown to be a compound heterozygote for two 
novel point mutations in the LCAT  gene resulting in the 
FED phenotype. Furthermore, we indicate that the 
incidence of atherosclerosis in patients with FED may be 
higher than previously assumed and also demonstrate 
that heterozygotes for this genetic defect may also be at 
increased risk.
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